Sugi Predict

Sugi Predict / Compounds / SCHEMBL474273

SCHEMBL474273

SCHEMBL474273

Nc1nnc(-c2ccc(Br)cc2)s1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 10/20 0.66
▸ MGAM O43451 5/20 0.66
▸ GAA P10253 5/20 0.66
▸ SI P14410 5/20 0.66
▸ MGAM2 Q2M2H8 5/20 0.66
▸ SMN1; SMN2 Q16637 5/20 0.66
▸ ALDH1A1 P00352 4/20 0.66
▸ LMNA P02545 2/20 0.66
▸ NOTUM Q6P988 1/20 0.66
▸ HSD17B10 Q99714 3/20 0.62
▸ HPGD P15428 2/20 0.62
▸ RAB9A P51151 6/20 0.59
▸ NPC1 O15118 4/20 0.59
▸ MAPT P10636 3/20 0.59
▸ TP53 P04637 2/20 0.59
▸ CSNK2A2 P19784 1/20 0.58
▸ CSNK2B P67870 1/20 0.58
▸ CSNK2A1 P68400 1/20 0.58
▸ L3MBTL1 Q9Y468 2/20 0.55
▸ CA1 P00915 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15618126 0.84 CA1 (0.56) KDM4EMGAMGAASIMGAM2
SCHEMBL28851907 0.83 KDM4E (0.70) KDM4EMGAMGAASIMGAM2
SCHEMBL20522295 0.81 CSNK2A2 (0.60) KDM4EMGAMGAASIMGAM2
SCHEMBL11340093 0.79 MGAM (1.00) KDM4EMGAMGAASIMGAM2
SCHEMBL1143313 0.79 KDM4E (0.66) KDM4EMGAMGAASIMGAM2
SCHEMBL23918236 0.79 KDM4E (0.66) KDM4EMGAMGAASIMGAM2
SCHEMBL1143676 0.79 KDM4E (1.00) KDM4EMGAMGAASIMGAM2
SCHEMBL6902047 0.79 ALDH1A1 (1.00) KDM4EMGAMGAASIMGAM2
SCHEMBL6538646 0.79 KDM4E (0.66) KDM4EMGAMGAASIMGAM2
SCHEMBL17725821 0.79 KDM4E (0.66) KDM4EMGAMGAASIMGAM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001873-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2026-01-01 — — US disclosed
US-12384772-B2 Inhibitors VIVORYON THERAPEUTICS N.V. (DE) 2025-08-12 — — US disclosed
CN-117024352-A Novel inhibitors 维沃里翁治疗股份有限公司 2023-11-10 — — CN disclosed
CN-112279845-B Aryl or heteroaryl substituted thiadiazoles compounds and antibacterial application thereof 中国医学科学院药物研究所 2023-07-28 — — CN disclosed
US-20220274977-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2022-09-01 — — US disclosed
US-11339152-B2 Inhibitors VIVORYON THERAPEUTICS N.V. 2022-05-24 — — US disclosed
CN-114507194-A 5-substituted-1, 3, 4-thiadiazole amide derivative and preparation method and application thereof 天津科技大学 2022-05-17 — — CN disclosed
CN-112920181-A N- (5-phenyl-1, 3, 4-thiadiazole-2-yl) benzamide compound 中国医科大学 2021-06-08 — — CN disclosed
CN-112279845-A Aryl or heteroaryl substituted thiadiazole compounds and antibacterial application thereof 中国医学科学院药物研究所 2021-01-29 — — CN disclosed
US-20170217923-A1 THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2017-08-03 — — US disclosed
US-7951814-B2 Quinazolinedione derivatives as TRPA1 modulators GLENMARK PHARMACEUTICALS, S.A. (CH) 2011-05-31 — — US disclosed
US-20110034521-A1 COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-02-10 — — US disclosed
WO-2010109328-A1 ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2010-09-30 — — WO disclosed
WO-2010109334-A2 THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2010-09-30 — — WO disclosed
WO-2010109329-A1 FUROPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2010-09-30 — — WO disclosed
WO-2010043377-A1 NEW 2-AMIDOTHIADIAZOLE DERIVATIVES ALMIRALL, S.A. (ES) 2010-04-22 — — WO disclosed
EP-2177521-A1 New 2-Amidothiadiazole Derivatives Almirall, S.A. (ES) 2010-04-21 — — EP disclosed
US-20090325987-A1 QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2009-12-31 — — US disclosed
WO-2009118596-A2 PHTHALIMIDE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S. A. (CH) 2009-10-01 — — WO disclosed
WO-2009090548-A2 3-AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS GLENMARK PHARMACEUTICALS, S.A. (US) 2009-07-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001873-A1 NOVEL INHIBITORS GLS, GLS2, SULT1E1 KDM4E 1773/4885MGAM 1369/4885GAA 674/4885
US-20110034521-A1 COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES MMP7, MMP3, MMP9 KDM4E 1274/4885MGAM 360/4885GAA 43/4885
US-11339152-B2 Inhibitors GLUL, QPCT, GLS KDM4E 1078/4885MGAM 349/4885GAA 281/4885
US-12384772-B2 Inhibitors GLS, QPCT, GLS2 KDM4E 1254/4885MGAM 158/4885GAA 171/4885
US-20090325987-A1 QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS TRPA1, TRPV1, TRPC3 KDM4E 4660/4885MGAM 4828/4885GAA 3316/4885
US-20220274977-A1 NOVEL INHIBITORS GLUL, GLS, QPCT KDM4E 1160/4885MGAM 379/4885GAA 251/4885
US-20170217923-A1 THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP4C, PTPRG, PPP2CA KDM4E 1215/4885MGAM 2828/4885GAA 339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.